Voyager Therapeutics, Inc.
VYGR
Rank in Stocks
#18796
Voyager Therapeutics, Inc. operates as a gene therapy company, concentrating... Voyager Therapeutics, Inc. operates as a gene therapy company, concentrating its efforts on developing innovative treatments and pioneering advanced platform technologies. Its leading clinical asset, VY-AADC, is presently undergoing an open-label Phase 1 clinical trial for the management of Parkinson's disease. The company's preclinical portfolio is extensive, featuring VY-SOD102 for amyotrophic lateral sclerosis (ALS), VY-HTT01 for Huntington's disease, and VY-FXN01 for Friedreich's ataxia. Additionally, Voyager is pursuing a Tau program aimed at various tauopathies, including Alzheimer's disease, progressive supranuclear palsy, and frontotemporal dementia, alongside initiatives for spinal muscular atrophy. To advance its gene therapy product pipeline, the company has forged strategic collaboration and licensing agreements with key industry players such as Neurocrine Biosciences, Inc., Pfizer Inc., and Novartis Pharma, A.G. These partnerships cover the research, development, and commercialization of adeno-associated virus-based gene therapy products. Voyager Therapeutics, Inc. was founded in 2013 and maintains its corporate headquarters in Cambridge, Massachusetts.
Share Price
$1.99
Last synced: 2026-11-09
Market Cap
$122.62M
Change (1 day)
6.70%
Change (1 year)
-53.18%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Voyager Therapeutics, Inc. (VYGR)
Category
Healthcare
EPS for Voyager Therapeutics, Inc. (VYGR)
EPS as of September 2026 TTM: $-1.74
According to Voyager Therapeutics, Inc.'s latest financial reports, its current EPS (TTM) is $-1.74. At the end of 2025 the company had an EPS of $-2.04, a decrease compared to its 2024 EPS of $-1.13.
EPS history for Voyager Therapeutics, Inc. from 2013 to 2026
EPS at the end of each year
| Year | EPS | Change |
|---|---|---|
| 2026 (TTM) | $-1.74 | -14.71% |
| 2025 | $-2.04 | 80.53% |
| 2024 | $-1.13 | -136.69% |
| 2023 | $3.08 | -354.55% |
| 2022 | $-1.21 | -30.86% |
| 2021 | $-1.75 | -276.77% |
| 2020 | $0.99 | -186.84% |
| 2019 | $-1.14 | -58.55% |
| 2018 | $-2.75 | 4.17% |
| 2017 | $-2.64 | 66.04% |
| 2016 | $-1.59 | -77.54% |
| 2015 | $-7.08 | 537.84% |
| 2014 | $-1.11 | -93.29% |
| 2013 | $-16.55 | 0.00% |
EPS for similar companies or competitors
| Company | EPS | EPS Difference | Country |
|---|---|---|---|
| $15.66 | -1,000.00% |
US
|
|
| $-7.07 | 306.32% |
US
|
|
| $-5.29 | 204.02% |
AU
|
|
| $12.88 | -840.24% |
BE
|
|
| $21.56 | -1,339.08% |
NL
|
Questions about Voyager Therapeutics, Inc.'s earnings per share (EPS)
What is Voyager Therapeutics, Inc.'s earnings per share (EPS)?
Voyager Therapeutics, Inc.'s earnings per share (EPS) over the last twelve months is $-1.74, as of Sep 2026.
What was Voyager Therapeutics, Inc.'s earnings per share (EPS) in 2025?
In 2025, Voyager Therapeutics, Inc.'s earnings per share (EPS) was $-2.04, compared with $-1.13 in 2024.
How has Voyager Therapeutics, Inc.'s earnings per share (EPS) changed since 2020?
From 2020 to 2025, Voyager Therapeutics, Inc.'s earnings per share (EPS) was highest in 2023 ($3.08) and lowest in 2025 ($-2.04).
How does Voyager Therapeutics, Inc.'s earnings per share (EPS) compare with similar companies?
Voyager Therapeutics, Inc.'s earnings per share (EPS) ($-1.74) is higher than that of 2 of the 5 similar companies listed above. The highest among them is Argenx SE, with $21.56.